iRhythm (IRTC) Q1 2026 Earnings Transcript

iRhythm posted Q1 revenue of $199.4 million, up 25.7% year over year, with adjusted EBITDA margin expanding 880 bps to 7.1% and gross margin improving 210 bps to 70.9%. Management raised full-year 2026 revenue guidance to $875 million-$885 million and adjusted EBITDA margin guidance to 12%-13%, while also highlighting progress on the next-gen MCT launch, AI algorithm approvals, and workflow efficiencies. Offsetting the strong operating performance are ongoing FDA warning letter remediation, DOJ CID uncertainty, and pending reimbursement/lcd issues.

Analysis

The key read-through is that iRhythm is no longer just a top-line story; it is beginning to look like a cash-flow compounding platform with operating leverage coming from three layers at once: manufacturing automation, workflow compression, and channel mix. The second-order implication is that every incremental unit of volume is increasingly more valuable than the last, which raises the probability that consensus is still underestimating mid-cycle margin power rather than merely current-quarter execution. That matters because the market tends to value medtech growth on revenue durability, but this print argues for a higher-quality earnings stream as scale and software-like efficiencies accrue.

The next-gen algorithm is the real optionality catalyst, but it is not a near-term P&L item until paired with the MCT launch in 2027. The important nuance is that the algorithm should widen the economic moat in two ways: it lowers labor intensity and it makes the installed base stickier by embedding proprietary analytics into the workflow, making displacement harder even if a software-only entrant emerges. In other words, AI here is defensive before it is offensive; the company is using data to reduce service cost, not just to create a feature.

The biggest underappreciated upside is regulatory/reimbursement convexity. If the proposed LCD ultimately clarifies toward more permissive long-term monitoring coverage, the company could see a step-function mix benefit without needing commensurate share gains, because category migration is a volume lever with limited incremental go-to-market spend. Conversely, the real tail risk is not weak demand but a reset in compliance/regulatory headlines, which would compress the multiple before fundamentals show up; that risk sits over the next 1-3 quarters, while the MCT/algorithm payoff is a 12-24 month story.

Key Decisions for Investors

• Long IRTC into the next 2-6 weeks on any post-earnings digestion, targeting a higher multiple if the market starts capitalizing 2027 margin expansion; risk is headline-driven pullbacks on FDA/DOJ noise, which should be bought only if volume remains intact.
• Buy IRTC Jan-2027 calls or call spreads to express the MCT + algorithm convexity; best risk/reward is a defined-risk structure because the rerating depends on 2027 implementation, not near-term revenue surprise.
• Pair trade: long IRTC / short a lower-quality medtech beneficiary with less operating leverage and weaker data moat over the next 3-6 months; thesis is that iRhythm’s mix of growth + expanding margins should outperform names whose AI exposure is more commoditized.
• If the final LCD language turns favorable, add to IRTC immediately on confirmation; that is the cleanest catalyst for a fast re-rating because it can lift addressable volume without extra sales spend.
• Use regulatory headline weakness as a tactical buy, but size small until the DOJ/CID and warning-letter overhang is fully resolved; the fundamental risk/reward is attractive, but timing risk remains high in the next quarter.